CSCI Stock Overview
A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
COSCIENS Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.93 |
| 52 Week High | CA$15.13 |
| 52 Week Low | CA$3.75 |
| Beta | 2.19 |
| 1 Month Change | -5.98% |
| 3 Month Change | -29.32% |
| 1 Year Change | -62.92% |
| 3 Year Change | -92.85% |
| 5 Year Change | -96.36% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely
May 10
We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow
Nov 12Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
Jul 15Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth
Mar 29Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years
Feb 04Shareholder Returns
| CSCI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -6.4% | -1.8% | -3.7% |
| 1Y | -62.9% | 15.3% | 15.0% |
Return vs Industry: CSCI underperformed the Canadian Biotechs industry which returned 13.6% over the past year.
Return vs Market: CSCI underperformed the Canadian Market which returned 16.7% over the past year.
Price Volatility
| CSCI volatility | |
|---|---|
| CSCI Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 12.9% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: CSCI has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CSCI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Gilles Gagnon | www.cosciensbio.com |
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
COSCIENS Biopharma Inc. Fundamentals Summary
| CSCI fundamental statistics | |
|---|---|
| Market cap | CA$12.18m |
| Earnings (TTM) | -CA$33.40m |
| Revenue (TTM) | CA$6.96m |
1.8x
P/S Ratio-0.4x
P/E RatioIs CSCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSCI income statement (TTM) | |
|---|---|
| Revenue | US$4.83m |
| Cost of Revenue | US$668.00k |
| Gross Profit | US$4.17m |
| Other Expenses | US$27.38m |
| Earnings | -US$23.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.43 |
| Gross Margin | 86.18% |
| Net Profit Margin | -480.12% |
| Debt/Equity Ratio | 0% |
How did CSCI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 19:10 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
COSCIENS Biopharma Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Byron Capital Markets |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Maher Yaghi | Desjardins Securities Inc. |